Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) was downgraded by investment analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a report released on Thursday, The Fly reports.
Several other equities research analysts have also recently issued reports on the company. Credit Suisse Group AG reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Sunday, June 12th. Cowen and Company reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Sunday, June 12th. Leerink Swann reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Sunday, June 12th. Barclays PLC cut Alnylam Pharmaceuticals from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $85.00 to $50.00 in a research note on Thursday. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $152.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, July 25th. Six analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $106.13.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 70.30 on Thursday. Alnylam Pharmaceuticals has a 1-year low of $49.96 and a 1-year high of $110.75. The firm’s market capitalization is $6.03 billion. The stock has a 50 day moving average price of $72.86 and a 200 day moving average price of $66.46.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.24) by $0.19. Alnylam Pharmaceuticals had a negative return on equity of 29.60% and a negative net margin of 1,204.91%. The company earned $8.70 million during the quarter, compared to analysts’ expectations of $8.09 million. During the same quarter in the previous year, the company posted ($0.85) earnings per share. The business’s revenue was up .2% on a year-over-year basis. Equities research analysts anticipate that Alnylam Pharmaceuticals will post ($4.64) earnings per share for the current fiscal year.
In related news, CEO John Maraganore sold 30,151 shares of the stock in a transaction on Wednesday, July 20th. The stock was sold at an average price of $64.69, for a total value of $1,950,468.19. Following the completion of the sale, the chief executive officer now directly owns 148,465 shares in the company, valued at $9,604,200.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 4.00% of the stock is owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of the stock. Nisa Investment Advisors LLC bought a new stake in Alnylam Pharmaceuticals during the second quarter worth $128,000. Seven Eight Capital LLC increased its stake in Alnylam Pharmaceuticals by 200.0% in the first quarter. Seven Eight Capital LLC now owns 2,700 shares of the biopharmaceutical company’s stock worth $169,000 after buying an additional 1,800 shares during the last quarter. Meeder Asset Management Inc. bought a new stake in Alnylam Pharmaceuticals during the second quarter worth $175,000. Bank of Montreal Can bought a new stake in Alnylam Pharmaceuticals during the second quarter worth $193,000. Finally, BlueMountain Capital Management LLC increased its stake in Alnylam Pharmaceuticals by 89.3% in the first quarter. BlueMountain Capital Management LLC now owns 3,179 shares of the biopharmaceutical company’s stock worth $200,000 after buying an additional 1,500 shares during the last quarter. Institutional investors and hedge funds own 85.96% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.